MediWound highlights consensus supporting wound treatment strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement
April 13, 2026 7:30 AM EDTNewly Published U.S. Expert Consensus Aligns with MediWounds Strategy for Chronic Wound Debridement
Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive biologically active driver of wound healing
Panel supports early use of effective, less invasive treatments in chronic wound care, reinforcing the commercial thesis for EscharEx® in chronic wound care
YAVNE, Israel, April 13, 2026 MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today highlighted the publication of a peer-reviewed... More
